Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

To see which oncology / CNS drug patents face expiration in Brazil

— Business development coordinator, pharmaceutical lab, USA

For information about when drugs will be coming off patent

— Pharmacist, UK

Better understanding of company drug patent expirations for investing purposes

— Analyst, USA

To know the patent status of branded drugs to assist with reserve planning for large claims

— Medical director at managed care organiziation, USA

To get information on brands we work on currently or could potentially work on

— Marketing professional, USA

Generated: May 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,858,650

« Back to Dashboard

Which drugs does patent 6,858,650 protect, and when does it expire?


Patent 6,858,650 protects TOVIAZ and is included in one NDA. There has been one Paragraph IV challenge on Toviaz.

This patent has sixty-nine patent family members in twenty-nine countries.

Summary for Patent: 6,858,650

Title: Stable salts of novel derivatives of 3,3-diphenylpropylamines
Abstract:The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for the manufacture and highly pure, stable intermediate products. The method is in particular characterized by regio- and chemoselectivity and high yield. Salts of phenolic monoesters of 3,3-diphenylpropylamines are provided, that are particularly well-suited for use in pharmaceutical formulations. Preferred compounds are R-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenylisobutyr ate ester hydrogen fumarate and R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyra te ester hydrochloride hydrate. Furthermore, stable, crystalline intermediate products that are essential for obtaining the abovementioned salts are provided. A preferred intermediate product is R-(-)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester.
Inventor(s): Meese; Claus (Monheim, DE)
Assignee: Schwarz Pharma AG (DE)
Application Number:10/130,214
Patent Claim Types:
see list of patent claims		Compound; Formulation; Use;

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pfizer
TOVIAZ
fesoterodine fumarate
TABLET, EXTENDED RELEASE;ORAL022030-001Oct 31, 2008ABRXYesNo6,858,650► SubscribeY TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
Pfizer
TOVIAZ
fesoterodine fumarate
TABLET, EXTENDED RELEASE;ORAL022030-002Oct 31, 2008ABRXYesYes6,858,650► SubscribeY TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,858,650

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany199 55 190Nov 16, 1999
PCT Information
PCT FiledNovember 15, 2000PCT Application Number:PCT/EP00/11309
PCT Publication Date:May 25, 2001PCT Publication Number: WO01/35957

International Patent Family for Patent: 6,858,650

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria286872► Subscribe
Austria337293► Subscribe
Austria395056► Subscribe
Australia2666701► Subscribe
Australia778132► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

To get information on international drug patents

— Patent agent, USA

To check for Australian drug patents

— Big Pharma, Ireland

To obtain a list of all currently off-patent approved small molecule therapeutics or those that will come off patent in the next 5 years

— Licensing / business development, Saudi Arabia

To obtain patent expiration information, so that the timeline for registration and launch of our generic products can be optimized.

— Business development manager, generics distribution company, Singapore

To proactively manage the hospital's pharmaceutical inventory

— Hospital pharmacist, USA

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot